Biotechnology
Commented by Fabian Lorenz on December 15th, 2025 | 07:25 CET
Alarm bells ringing at Evotec! BioNTech and Vidac Pharma achieve success in the fight against cancer! Analysts recommend buying!
Alarm bells are ringing at Evotec. A major shareholder has completely withdrawn from the German biotech company. The security is trading at 2016 levels. Vidac Pharma, on the other hand, has reached a milestone. In the EU, the Phase 2b clinical trial for the ointment Tuvatexib (VDA1102) against a particularly active, fast-growing precursor of skin cancer can begin. BioNTech is also continuing the fight against cancer. Initial results from the global Phase 2 trial of the non-specific antibody candidate Pumitamig showed encouraging anti-tumor activity in advanced triple-negative breast cancer. Analysts recommend buying shares in Vidac and BioNTech.
Read
Commented by Carsten Mainitz on December 11th, 2025 | 07:20 CET
On the winning side – now and in 2026: Antimony Resources and Bayer, crash at Evotec!
The year 2025 is drawing to a close. It is time to focus on stocks and investment themes that could offer attractive returns in 2026. Trends such as AI, defense, and robotics are expected to continue. Further involvement in the commodities sector also appears lucrative. Here, investors can find an exciting second-tier investment story in the still largely undiscovered Canadian company Antimony Resources. But opportunities also exist in the blue-chip segment. Bayer has established a solid foundation this year, and analysts have recently raised their price targets significantly. For heavily punished stocks like Evotec, a turnaround could also emerge next year.
Read
Commented by Nico Popp on December 9th, 2025 | 07:05 CET
Attacking the fuel that feeds tumors: Why Roche, Pfizer, and Vidac Pharma are redefining oncology
Modern cancer therapy is no longer about blunt-force attacks, but rather precise, targeted interventions. While oncology in recent decades has been dominated by non-specific cell toxins, today's research resembles surgical intervention in the biological software of a disease. Industry heavyweights, Roche and Pfizer, are securing their market positions with gigantic portfolios of immunotherapies. But away from the corporate headquarters of Basel and New York, agile biotech pioneers are working on approaches that attack the very foundation of cancer cells: their energy supply. Those who pull the plug on cancer cells could be among the big winners in the biotech sector in 2026.
Read
Commented by Fabian Lorenz on December 8th, 2025 | 07:15 CET
RENK better than HENSOLDT? Risk at NOVO NORDISK! Billion-dollar opportunity with RZOLV Technologies!?
Is RENK's stock better than Hensoldt's? That is what analysts are saying. According to them, the transmission specialist is attractively valued at the current level. Hensoldt, on the other hand, is having problems converting its order backlog into revenue growth, leading to a significant reduction in its price target. In contrast, RZOLV Technologies shares have enormous upside potential. The Company aims to replace a toxic chemical used in gold extraction, thereby opening up a billion-dollar market. Development is nearly complete, and patents have been filed. In just a few months, RZOLV could become a hot takeover candidate. Meanwhile, takeovers currently appear to be a way for Novo Nordisk to replenish its drug pipeline, with the Danish company taking risks worth billions - Pfizer, take note.
Read
Commented by Armin Schulz on December 8th, 2025 | 07:15 CET
Leveraging AI revenue potential: The master plan from Novo Nordisk, Aspermont, and Deutsche Telekom
Artificial intelligence is permeating the economy and creating an unprecedented productivity boost. Efficiency gains of 25% in manufacturing and savings of one trillion dollars by 2030 in supply chains are just the beginning. This growth potential of up to 0.8 percentage points per year leverages the profitability of pioneers and clearly separates them from the rest of the market. Who are the pioneers who are already applying this disruptive force today and will translate it into concrete profits in the future? Three companies are leading the way: Novo Nordisk, Aspermont, and Deutsche Telekom.
Read
Commented by Fabian Lorenz on December 3rd, 2025 | 10:20 CET
US government strengthens Bayer! Almonty next? What is Novo Nordisk doing?
A bombshell at Bayer: The US government has officially sided with the Company. If the Supreme Court follows the recommendation, the Leverkusen-based company could largely put the glyphosate issue behind it as early as next year. Investors and analysts are enthusiastic. Almonty Industries is also in intensive discussions with the US government. CEO Lewis Black emphasized this in an interview with Fox Business. The Company plans to start mining tungsten, which is critical for defense and aerospace, among other things, in the US as early as next year. Since 2015, the US has been 100% dependent on imports. Analysts see 40% upside potential. Novo Nordisk shares are currently looking for a bottom. To reduce its dependence on Ozempic, the Danes have concluded a billion-dollar deal.
Read
Commented by Armin Schulz on December 2nd, 2025 | 07:00 CET
The demographic clock is ticking: How Bayer, Vidac Pharma, and Novo Nordisk are positioning themselves in the billion-dollar battle for our health
The demographic clock is ticking inexorably. An aging society brings with it a flood of widespread diseases such as heart disease, cancer, and diabetes. Each one is a billion-dollar market that is pushing healthcare systems to their limits. As costs explode, brutal, cut-throat competition is emerging. The winner will not be the one with the most pills, but the one with the most effective solutions to the greatest medical and economic challenges of our time. Today, we take a look at how Bayer, Vidac Pharma, and Novo Nordisk plan to shape the future.
Read
Commented by André Will-Laudien on November 27th, 2025 | 07:55 CET
Black Friday: DAX explodes, and biotech is back in vogue: Watch out for 100% gains at Bayer, Vidac Pharma, and Novo Nordisk
The stock market has managed to break out of its consolidation phase, and the upward trend is continuing toward the end of the year. There are signs of hope for the Leverkusen-based pharmaceutical company Bayer, and Vidac Pharma is moving into the primary segment of the Düsseldorf over-the-counter market. The well-known Novo Nordisk, whose share price has been destroyed, is experiencing its fourth sell-off in three months. Some analysts are now turning positive. Investors should now be aware that prices in the biotech sector have fallen so low that even minor news items are enough to cause prices to skyrocket. Especially during the year-end portfolio adjustments, prices often reach absurd levels. We help you navigate the thicket of valuations.
Read
Commented by André Will-Laudien on November 18th, 2025 | 07:25 CET
Nvidia figures ahead, AI correction looming? Doubling alternatives include Planethic Group, Bayer, Eli Lilly, and Novo Nordisk
It does not always have to be Nvidia! If the current level of risk on the NASDAQ feels a bit too high, investors should take a look at some European gems. There may be less AI involved here, but people still work for people. This is particularly interesting as Elon Musk aims to equip the core zone of human interaction with humanoid robots, from cooking together in the kitchen to family life, which could receive "digital offspring" as early as 2027. Because the planet will soon face food and water shortages due to permanent overheating, we are taking a closer look at completely analog topics such as alternative nutrition and the prevention of obesity. This is certainly too boring for the disciples of the digital apocalypse, but it offers plenty of charm for non-digital investors.
Read
Commented by Carsten Mainitz on November 18th, 2025 | 07:10 CET
Takeover fever! LAURION Mineral Exploration, Evotec, and Mutares are tempting investors to get on board!
M&A – mergers and acquisitions - remain powerful performance drivers for shareholders of potential takeover targets. But companies that acquire others also benefit from increased growth, access to new markets and technologies, and cost synergies. According to a recent study by Bain & Company, the majority of M&A activity in the current year, amounting to around USD 265 billion, has taken place in the energy and commodities sectors. In healthcare and life sciences, deals with a volume of USD 107 billion were recorded. So who could the next takeover candidates be?
Read